Latest News On FDA

Latest KFF Health News Stories

Hidden FDA Reports Detail Harm Caused By Scores Of Medical Devices

KFF Health News Original

The Food and Drug Administration has let medical device companies file reports of injuries and malfunctions outside a widely scrutinized public database, leaving doctors and medical sleuths in the dark.

Ciudades y condados seguirán importando medicamentos, a pesar de alertas de la FDA

KFF Health News Original

Varios estados, entre ellos Florida y Nueva York, dijeron que continuarán usando una compañía canadiense para ofrecer a sus empleados medicamentos recetados a bajo precio.

Pacientes experimentan con drogas recetadas para luchar contra la vejez

KFF Health News Original

Aún no se han realizado ensayos clínicos rigurosos a gran escala para estudiar el proceso de envejecimiento. Así y todo, pacientes experimentan con drogas para detener el paso del tiempo.

Cities And Counties Unlikely To Heed FDA Warning On Importing Foreign Drugs

KFF Health News Original

The Food and Drug Administration claims CanaRX, a company used by more than 500 cities, counties and school districts to help their employees get cheaper drugs from overseas, has sent “unapproved” and “misbranded” drugs to U.S. consumers, jeopardizing their safety.

Patients Question How FDA Approves Medical Devices

KFF Health News Original

High-profile failures of implantable medical devices — such as certain hip joints and pelvic mesh — have prompted the Food and Drug Administration to revise its assessment process.

Podcast: KHN’s ‘What The Health?’ How Safe Are Your Supplements?

KFF Health News Original

Alice Ollstein of Politico, Kimberly Leonard of the Washington Examiner and Anna Edney of Bloomberg News join KHN’s Julie Rovner to discuss the latest national health spending estimates, another FDA crackdown on dietary supplements and lawsuits between insurers and the federal government that could result in a windfall for consumers.

¿La fuente de la juventud en una píldora? Sí, si eres un ratón

KFF Health News Original

Separar la realidad de la exageración en el campo que estudia la longevidad se ha vuelto más difícil que nunca, más ahora que prestigiosas instituciones incursionan en ese campo.

Podcast: KHN’s ‘What The Health?’ New Year, New Health Proposals

KFF Health News Original

Democratic governors and mayors are unveiling new ideas to control costs and expand coverage. The federal government shutdown has spared most health agencies, but not all. And learn the latest on that lawsuit out of Texas, which is threatening the Affordable Care Act once again. Margot Sanger-Katz of The New York Times, Anna Edney of Bloomberg News and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and, for “extra credit,” provide their favorite health policy stories of the week. Rovner also interviews KHN’s Jordan Rau about the latest “Bill of the Month.”

When Medicine Makes Patients Sicker

KFF Health News Original

The Food and Drug Administration is supposed to inspect all factories, foreign and domestic, that produce drugs for the U.S. market. But a KHN review of thousands of FDA documents — inspection records, recalls, warning letters and lawsuits — reveals how drugs that are poorly manufactured or contaminated can reach consumers.

How The Government Shutdown Affects Health Programs

KFF Health News Original

Medicare and Medicaid are fine, but the food safety component of the Food and Drug Administration and bio-threat surveillance done by the Department of Homeland Security are among the public health functions feeling the pinch.

5 Ways Nixing The Affordable Care Act Could Upend The Entire Health System

KFF Health News Original

There could be a long legal struggle ahead over the decision by a judge in Texas to invalidate the federal health law. But if his decision stands, it would have long-lasting effects on health care from insurance coverage to Medicare payments to privacy protections.

Why The U.S. Remains The World’s Most Expensive Market For ‘Biologic’ Drugs

KFF Health News Original

Biologic drugs, made from living organisms, are big moneymakers partly because they have little competition from “biosimilars.” It’s a very different story in Europe.